Acute Myeloid Leukemia (AML) Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Acute Myeloid Leukemia (AML) Epidemiology Forecast Report Coverage

Expert Market Research's “Acute Myeloid Leukemia (AML) Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of acute myeloid leukemia (AML). It projects the future incidence and prevalence rates of acute myeloid leukemia (AML) cases across various populations. The study covers age, gender, and type as major determinants of the acute myeloid leukemia (AML) population. The report highlights patterns in the prevalence of acute myeloid leukemia (AML) over time and projects future trends based on multiple variables.

Acute Myeloid Leukemia (AML) Understanding: Disease Overview

Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by clonal proliferation of immature myeloid precursors in the bone marrow, leading to marrow failure and systemic complications. AML primarily affects older adults, though it can occur at any age. Genetic and molecular abnormalities, including mutations in FLT3, NPM1, and IDH1/2, define disease subtypes and influence prognosis. Clinical presentation includes fatigue, anemia, infections, and bleeding. Diagnosis is based on bone marrow morphology, immunophenotyping, and cytogenetic testing, guiding individualized treatment strategies.

Acute Myeloid Leukemia (AML) Epidemiology Perspective

The acute myeloid leukemia (AML) epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the acute myeloid leukemia (AML) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for acute myeloid leukemia (AML) and their trends. The acute myeloid leukemia (AML) detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• A 2024-2025 multinational analysis reports subtype-specific incidence for leukemia (including AML) for 2022, with adult AML age-standardized rates (ASR) of 3.1 per 100,000 in males and 2.4 per 100,000 in females among adults.
• Proportion of AML among leukemias is increasing. It rose from 18.0% of total leukemias in 1990 to 23.1% in 2017 globally.
• AML is primarily a disease of older adults, median age at diagnosis ≈68–69 years in high-income registries; incidence rises steeply with age.
• Incidence and mortality are slightly higher in males than females across regions.
• Prognosis varies widely by patient age, comorbidities, cytogenetics/molecular subtype, and treatment (including stem cell transplant eligibility). Older patients typically fare much worse.

Read more about this report - Request a Free Sample

Country-wise Acute Myeloid Leukemia (AML) Epidemiology Segment

The acute myeloid leukemia (AML) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

In the United States, acute myeloid leukemia (AML) continues to pose a significant hematologic burden. In 2025, approximately 22,010 new AML cases were reported nationwide. The age-standardized incidence rate was around 3.85 per 100,000 population, reflecting a steady increase with advancing age. The disease primarily affects older adults, with a median diagnosis age of approximately 68-69 years. AML occurs slightly more often in males than in females, and its incidence rises sharply in individuals aged 55 years and older, emphasizing the age-dependent nature of this malignancy.

Acute Myeloid Leukemia (AML): Treatment Overview

The management of AML involves rapid initiation of chemotherapy aimed at achieving complete remission. Standard induction therapy combines cytarabine with anthracyclines (“7+3” regimen). For consolidation, high-dose cytarabine or allogeneic hematopoietic stem-cell transplantation is considered, depending on risk stratification. Targeted agents such as midostaurin, gilteritinib, and enasidenib address specific molecular alterations, while venetoclax-based regimens have improved outcomes in older or unfit patients. Advances in molecular profiling continue to refine therapy, aiming to enhance remission rates and reduce relapse.

Key Questions Answered

• What are the key findings of acute myeloid leukemia (AML) epidemiology in the 8 major markets?
• What will be the total number of patients with acute myeloid leukemia (AML) across the 8 major markets during the forecast period?
• What was the country-wise acute myeloid leukemia (AML) epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of acute myeloid leukemia (AML) during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of acute myeloid leukemia (AML) during the forecast period of 2026-2035?
• What are the currently available treatments for acute myeloid leukemia (AML)?
• What are the disease risks, signs, symptoms, and unmet needs of acute myeloid leukemia (AML)?

Scope of the Acute Myeloid Leukemia (AML) Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of acute myeloid leukemia (AML) based on several factors.
• Acute Myeloid Leukemia (AML) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The acute myeloid leukemia (AML) report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Acute Myeloid Leukemia Pipeline Analysis

Acute Myeloid Leukemia Market